Seladelpar improves symptoms of primary biliary cholangitis

Seladelpar improves symptoms of primary biliary cholangitis

1. In this randomized controlled trial, among patients with primary biliary cholangitis (PBC) who had had inadequate response to ursodeoxycholic acid, seladelpar was superior to placebo in achieving biochemical response and symptomatic management. 2. Seladelpar had an acceptable safety profile, with similar rates of adverse events to a placebo. Evidence Rating Level: 1 (Excellent) Study

Related Keywords

, Minute Medicine Inc , Rating Level , Confidence Interval , Chronic Disease , Gastroenterology , Immunology , Primary Biliary Cholangitis , Seladelpar , Ursodeoxycholic Acid ,

© 2025 Vimarsana